Treat-to-target in systemic lupus erythematosus: where are we today?

Marta Mosca, Dimitrios T. Boumpas, Ian N. Bruce, Ricard Cervera, Laszlo Czirjak, Thomas Dörner, Frédéric Houssiau, Soren Jacobsen, Matthias Schneider, Josef S. Smolen, Alexandre E. Voskuyl, Ronald F. van Vollenhoven, T. Dorner, AE Voskuyl

Research output: Contribution to journalArticleAcademicpeer-review

47 Citations (Scopus)


Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-to-target approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year
Original languageEnglish
Pages (from-to)S112-S115
JournalClinical and experimental rheumatology
Issue number4 Suppl 73
Publication statusPublished - 2012

Cite this